Health Care Professional Information
Zyflamend is a formulation containing ten different herbs. It is marketed as a dietary supplement for healthy inflammation response and normal cardiovascular and joint function (1). Preliminary studies suggest that the ingredients in Zyflamend have anti-inflammatory, antiangiogenic, and antiproliferative properties (2).
Zyflamend also inhibits the proliferation of oral squamous carcinoma (3), pancreatic cancer (4) and melanoma cells in vitro (5).
In an animal model, it inhibited the growth of both hormone-sensitive and hormone-insensitive prostate cancer, and reduced the expression of prostate specific antigen (PSA) (6).
In a Phase I trial in men with prostatic intraepithelial neoplasia (PIN), Zyflamend did not cause any serious adverse events nor significant changes in serum prostate specific antigen (PSA) nor tissue nuclear factor (NF)-kappa B levels. However, a significant reduction in serum levels of C-reactive protein was observed (7). More studies are warranted.
Zyflamend may potentiate the cytotoxic effects of certain chemotherapeutic agents, including gemcitabine (4), taxol (2), doxorubicin (2) and bicalutamide (8). Human data are lacking.
- Cancer treatment
Mechanism of Action
Holy basil, turmeric, ginger, green tea, rosemary, hu zhang, Chinese gold thread and Scutellaria inhibit cyclooxygenase-2 (COX-2) activity and thereby reduce inflammation. In vitro studies showed that Zyflamend inhibits inflammatory enzymes, decreases retinoblastoma (Rb) protein phosphorylation (9), and induces apoptosis in human prostate cancer cells (2)(3)(4)(10). Zyflamend also reduced androgen receptor signaling and enhanced bicalutamide-induced apoptosis in prostate cancer cell lines (8). In a murine xenograft model of prostate cancer, Zyflamend was shown to inhibit androgen-dependent tumor growth and histone deacetylase-5, biomarkers linked to prostate cancer progression (6).
Zyflamend reduced the number of inflammatory cells, hyperplasia and dysplasia, tumor incidence and number, and inhibited cell proliferation in an animal model of oral squamous cell carcinoma (3). It inhibited osteoclastogenesis and NF-kappa B activation in myeloid leukemia cells and in lung adenocarcinoma cells as well (2); it inhibited NF-kappa B activation and enhanced gemcitabine-induced apoptosis in pancreatic cancer cells (4).
An in vitro study showed that Zyflamend induces autophagy and apoptosis sequentially in melanoma cells by activating the intrinsic caspase cascade. Cell migration and COX-2 expression were also suppressed (5).
Reported: Bad taste in the mouth, heartburn, and diarrhea. (7)
The herbal constituents of Zyflamend can potentially interact with prescription drugs.
May increase the effects of gemcitabine (4), taxol (2), doxorubicin (2) and bicalutamide (8).
Dosage (Inside MSKCC Only)
This field is only visible to only Inside MSKCC users.
- New Chapter I. Zyflamend - Herbals from New Chapter. 2012; http://www.newchapter.com/zyflamend. Accessed June 29, 2012.
- Sandur SK, Ahn KS, Ichikawa H, et al. Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of NF-kappa B activation and NF-kappa B-regulated gene products. Nutr Cancer. 2007;57(1):78-87.
- Yang P, Sun Z, Chan D, et al. Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis. Nov 2008;29(11):2182-2189.
- Kunnumakkara AB, Sung B, Ravindran J, et al. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer. Aug 1 2012;131(3):E292-303.
- Ekmekcioglu S, Chattopadhyay C, Akar U, et al. Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutr Cancer. 2011;63(6):940-949.
- Huang EC, McEntee MF, Whelan J. Zyflamend, a Combination of Herbal Extracts, Attenuates Tumor Growth in Murine Xenograft Models of Prostate Cancer. Nutr Cancer. Jun 4 2012.
- Capodice JL, Gorroochurn P, Cammack AS, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol. Spring 2009;7(2):43-51.
- Yan J, Xie B, Capodice JL, et al. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. Prostate. Feb 2012;72(3):244-252.
- Yang P, Cartwright C, Chan D, et al. Zyflamend-mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb protein phosphorylation. Cancer Biol Ther. Feb 2007;6(2):228-236.
- Bemis DL, Capodice JL, Anastasiadis AG, et al. Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer. 2005;52(2):202-212.
How It Works
Bottom Line: Zyflamend has not been shown to treat cancer.
Zyflamend is a herbal supplement consisting of Holy basil, turmeric, ginger, green tea, rosemary, hu zhang, Chinese goldthread, barberry, oregano, and scullcap. Promoters of Zyflamend claim that it has anti-inflammatory and antiaging effects. It has been shown in one laboratory study to reduce inflammation and cause cell death. Results from a small study indicate it may help lower prostate specific antigen (PSA), a marker of prostate cancer. More research is needed.
- Cancer treatment
A lab study showed that Zyflamend can reduce the number of prostate cancer cells. Zyflamend did not cause serious adverse events in men with prostatic intraepithelial neoplasia (PIN). More research is needed.
A lab study showed that Zyflamend reduces inflammation but there are no data from clinical trials.
A laboratory study showed that Zyflamend reduced the number of prostate cancer cells by inactivating the inflammatory enzyme activity and by inducing cell death.
Do Not Take If
- You have hypersensitivity to any of the constituents
Bad taste in the mouth, heartburn, and diarrhea.
Last updated: June 29, 2012